© 1997 by Oxford University Press
Journal Of The National Cancer Institute, Vol 89, 166-170, Copyright © 1997 by Oxford University Press
SA Ingles, RK Ross, MC Yu, RA Irvine, G La Pera, RW Haile and GA Coetzee
BACKGROUND: Prostate cancer is an increasingly common disease for which
there are few well-established risk factors. Family history data suggest a
genetic component; however, the majority of prostate cancer cases cannot be
explained by a single-gene model. Prostate cell division is influenced by
two steroid hormones, testosterone and vitamin D, the action of each being
mediated by its respective receptor. The genes for the two receptors are
candidates in a multigenic model for prostate cancer susceptibility.
PURPOSE: We examined genetic polymorphisms in two steroid receptors, the
androgen receptor (AR) and the vitamin D receptor (VDR), in a case-control
pilot study of prostate cancer. METHODS: Fifty-seven non-Hispanic white
case patients with prostate cancer and 169 non-Hispanic white control
subjects were genotyped for a previously described microsatellite (CAG
repeats) in the AR gene and for a newly discovered poly-A microsatellite in
the 3'-untranslated region (3'UTR) of the VDR gene. To compare genotypes
with respect to prostate cancer risk, we estimated odds ratios (ORs) by
using logistic regression. ORs were also estimated separately for advanced
and localized cases of disease. All P values resulted from two-sided tests.
RESULTS: Both the AR and the VDR polymorphisms were associated,
individually and after mutual adjustment, with prostate cancer. Adjusted
ORs (95% confidence intervals [CIs]) for prostate cancer were 2.10 (95% CI
= 1.11-3.99) for individuals carrying an AR CAG allele with fewer than 20
repeats versus an allele with 20 or more repeats and 4.61 (95% CI =
1.34-15.82) for individuals carrying at least one long (A18 to A22) VDR
poly-A allele versus two short (A14 to A17) poly-A alleles. For both the AR
and VDR genes, the at-risk genotypes were more strongly associated with
advanced disease than with localized disease. CONCLUSIONS: In this pilot
study, genetic variation in both the VDR and the AR genes was associated
with prostate cancer, and both genes appear to preferentially confer risk
for advanced disease. These two genetic risk factors, if confirmed, are
among the strongest risk factors yet identified for prostate cancer.
IMPLICATIONS: These results are consistent with a multigenic model of
prostate cancer susceptibility. On the basis of the joint effect of several
genetic loci, one might ultimately be able to construct a risk profile to
predict advanced disease, so that men whose disease is unlikely to progress
to an advanced stage can possibly be spared aggressive treatment.
ARTICLES
Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor
Department of Preventive Medicine, Norris Comprehensive Cancer Center, University of Southern California School of Medicine, Los Angeles 90033- 0800, USA.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
K. KOSTNER, N. DENZER, C. S.L. MULLER, R. KLEIN, W. TILGEN, and J. REICHRATH The Relevance of Vitamin D Receptor (VDR) Gene Polymorphisms for Cancer: A Review of the Literature Anticancer Res, September 1, 2009; 29(9): 3511 - 3536. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. H. Onen, A. Ekmekci, M. Eroglu, E. Konac, S. Yesil, and H. Biri Association of Genetic Polymorphisms in Vitamin D Receptor Gene and Susceptibility to Sporadic Prostate Cancer Experimental Biology and Medicine, December 1, 2008; 233(12): 1608 - 1614. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wedren, C. Magnusson, K. Humphreys, H. Melhus, A. Kindmark, F. Stiger, M. Branting, I. Persson, J. Baron, and E. Weiderpass Associations between Androgen and Vitamin D Receptor Microsatellites and Postmenopausal Breast Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1775 - 1783. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Mullin and A. Dobs Vitamin D and Its Role in Cancer and Immunity: A Prescription for Sunlight Nutr Clin Pract, June 1, 2007; 22(3): 305 - 322. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Tuohimaa, L. Tenkanen, H. Syvala, S. Lumme, T. Hakulinen, J. Dillner, and M. Hakama Interaction of Factors Related to the Metabolic Syndrome and Vitamin D on Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 302 - 307. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Cicek, X. Liu, F. R. Schumacher, G. Casey, and J. S. Witte Vitamin D Receptor Genotypes/Haplotypes and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2549 - 2552. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sweeney, K. Curtin, M. A. Murtaugh, B. J. Caan, J. D. Potter, and M. L. Slattery Haplotype analysis of common vitamin d receptor variants and colon and rectal cancers. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 744 - 749. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Nam, W. W. Zhang, M. A.S. Jewett, J. Trachtenberg, L. H. Klotz, M. Emami, L. Sugar, J. Sweet, A. Toi, and S. A. Narod The Use of Genetic Markers to Determine Risk for Prostate Cancer at Prostate Biopsy Clin. Cancer Res., December 1, 2005; 11(23): 8391 - 8397. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Garolla, A Ferlin, C Vinanzi, A Roverato, G Sotti, W Artibani, and C Foresta Molecular analysis of the androgen receptor gene in testicular cancer Endocr. Relat. Cancer, September 1, 2005; 12(3): 645 - 655. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary Molecular pathology of prostate cancer J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. John, G. G. Schwartz, J. Koo, D. Van Den Berg, and S. A. Ingles Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Risk of Advanced Prostate Cancer Cancer Res., June 15, 2005; 65(12): 5470 - 5479. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Platz, M. F. Leitzmann, N. Rifai, P. W. Kantoff, Y.-C. Chen, M. J. Stampfer, W. C. Willett, and E. Giovannucci Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Prostate-Specific Antigen Era Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1262 - 1269. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Hayes, G. Severi, E. J.D. Padilla, S. A. Eggleton, M. C. Southey, R. L. Sutherland, J. L. Hopper, and G. G. Giles Genetic Variants in the Vitamin D Receptor Gene and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 997 - 999. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yamashita, S. Suzuki, T. Nomoto, Y. Kondo, K. Wakazono, Y. Tsujino, T. Sugimura, T. Shirai, Y. Homma, and T. Ushijima Linkage and Microarray Analyses of Susceptibility Genes in ACI/Seg Rats: A Model for Prostate Cancers in the Aged Cancer Res., April 1, 2005; 65(7): 2610 - 2616. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ferlin, A. Garolla, A. Bettella, L. Bartoloni, C. Vinanzi, A. Roverato, and C. Foresta Androgen receptor gene CAG and GGC repeat lengths in cryptorchidism Eur. J. Endocrinol., March 1, 2005; 152(3): 419 - 425. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Garber and K. Offit Hereditary Cancer Predisposition Syndromes J. Clin. Oncol., January 10, 2005; 23(2): 276 - 292. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Zeegers, L. A.L.M. Kiemeney, A. M. Nieder, and H. Ostrer How Strong Is the Association Between CAG and GGN Repeat Length Polymorphisms in the Androgen Receptor Gene and Prostate Cancer Risk? Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1765 - 1771. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Foley, D. Hollywood, and M. Lawler Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease Endocr. Relat. Cancer, September 1, 2004; 11(3): 477 - 488. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Oakley-Girvan, D. Feldman, T. R. Eccleshall, R. P. Gallagher, A. H. Wu, L. N. Kolonel, J. Halpern, R. R. Balise, D. W. West, R. S. Paffenbarger Jr., et al. Risk of Early-Onset Prostate Cancer in Relation to Germ Line Polymorphisms of the Vitamin D Receptor Cancer Epidemiol. Biomarkers Prev., August 1, 2004; 13(8): 1325 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ferlin, L. Bartoloni, G. Rizzo, A. Roverato, A. Garolla, and C. Foresta Androgen receptor gene CAG and GGC repeat lengths in idiopathic male infertility Mol. Hum. Reprod., June 1, 2004; 10(6): 417 - 421. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Wang, T. S. Udayakumar, T. S. Vasaitis, A. M. Brodie, and J. D. Fondell Mechanistic Relationship between Androgen Receptor Polyglutamine Tract Truncation and Androgen-dependent Transcriptional Hyperactivity in Prostate Cancer Cells J. Biol. Chem., April 23, 2004; 279(17): 17319 - 17328. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ntais, A. Polycarpou, and J. P. A. Ioannidis Vitamin D Receptor Gene Polymorphisms and Risk of Prostate Cancer: A Meta-analysis Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1395 - 1402. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Nam, W. W. Zhang, J. Trachtenberg, M. A. S. Jewett, M. Emami, D. Vesprini, W. Chu, M. Ho, J. Sweet, A. Evans, et al. Comprehensive Assessment of Candidate Genes and Serological Markers for the Detection of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1429 - 1437. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Liede, W. Zhang, M. L. D. L. Matsuda, A. Tan, and S. A. Narod Androgen Receptor Gene Polymorphism and Breast Cancer Susceptibility in the Philippines Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 848 - 852. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.A. Schulz, M. Burchardt, and M.V. Cronauer Molecular biology of prostate cancer Mol. Hum. Reprod., August 1, 2003; 9(8): 437 - 448. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Nam, W. W. Zhang, J. Trachtenberg, E. Diamandis, A. Toi, M. Emami, M. Ho, J. Sweet, A. Evans, M. A.S. Jewett, et al. Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer Detection J. Clin. Oncol., June 15, 2003; 21(12): 2312 - 2319. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Suter, K. E. Malone, J. R. Daling, D. R. Doody, and E. A. Ostrander Androgen Receptor (CAG)n and (GGC)n Polymorphisms and Breast Cancer Risk in a Population-Based Case-Control Study of Young Women Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 127 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xu, A. Shibata, J. E. McNeal, T. A. Stamey, D. Feldman, and D. M. Peehl Vitamin D Receptor Start Codon Polymorphism (FokI) and Prostate Cancer Progression Cancer Epidemiol. Biomarkers Prev., January 1, 2003; 12(1): 23 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Rebbeck Inherited Genotype and Prostate Cancer Outcomes Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 945 - 952. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Giovannucci Is the Androgen Receptor CAG Repeat Length Significant for Prostate Cancer? : Commentary re: C. Chen et al., Androgen Receptor Polymorphisms and the Incidence of Prostate Cancer. Cancer Epidemiol. Biomark. Prev., 11: 1033-1040, 2002 Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 985 - 986. [Full Text] [PDF] |
||||
![]() |
C. Chen, N. Lamharzi, N. S. Weiss, R. Etzioni, D. A. Dightman, M. Barnett, D. DiTommaso, and G. Goodman Androgen Receptor Polymorphisms and the Incidence of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 1033 - 1040. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gsur, M. Preyer, G. Haidinger, T. Zidek, S. Madersbacher, G. Schatzl, M. Marberger, C. Vutuc, and M. Micksche Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk Carcinogenesis, October 1, 2002; 23(10): 1647 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Bennett, D. K. Price, S. Kim, D. Liu, B. D. Jovanovic, D. Nathan, M. E. Johnson, J. S. Montgomery, K. Cude, J. C. Brockbank, et al. Racial Variation in CAG Repeat Lengths Within the Androgen Receptor Gene Among Prostate Cancer Patients of Lower Socioeconomic Status J. Clin. Oncol., September 1, 2002; 20(17): 3599 - 3604. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Yeh, C.-F. Chang, W.-Y. Shau, Y.-W. Chen, H.-C. Hsu, P.-H. Lee, D.-S. Chen, and P.-J. Chen Dominance of Functional Androgen Receptor Allele with Longer CAG Repeat in Hepatitis B Virus-related Female Hepatocarcinogenesis Cancer Res., August 1, 2002; 62(15): 4346 - 4351. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Giles, G. Severi, R. Sinclair, D. R. English, M. R. E. McCredie, W. Johnson, P. Boyle, and J. L. Hopper Androgenetic Alopecia and Prostate Cancer: Findings from an Australian Case-Control Study Cancer Epidemiol. Biomarkers Prev., June 1, 2002; 11(6): 549 - 553. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Nelson and J. S. Witte Androgen Receptor CAG Repeats and Prostate Cancer Am. J. Epidemiol., May 15, 2002; 155(10): 883 - 890. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Gelmann, D. J. Steadman, J. Ma, N. Ahronovitz, H. J. Voeller, S. Swope, M. Abbaszadegan, K. M. Brown, K. Strand, R. B. Hayes, et al. Occurrence of NKX3.1 C154T Polymorphism in Men with and without Prostate Cancer and Studies of Its Effect on Protein Function Cancer Res., May 1, 2002; 62(9): 2654 - 2659. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Haiman, M. Brown, S. E. Hankinson, D. Spiegelman, G. A. Colditz, W. C. Willett, P. W. Kantoff, and D. J. Hunter The Androgen Receptor CAG Repeat Polymorphism and Risk of Breast Cancer in the Nurses' Health Study Cancer Res., February 1, 2002; 62(4): 1045 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Martin, H. J. Voeller, E. P. Gelmann, J. Lu, E.-G. Stoica, E. J. Hebert, R. Reiter, B. Singh, M. Danielsen, E. Pentecost, et al. Role of Cadmium in the Regulation of AR Gene Expression and Activity Endocrinology, January 1, 2002; 143(1): 263 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Peters, K. A. McGlynn, N. Chatterjee, E. Gunter, M. Garcia-Closas, N. Rothman, and R. Sinha Vitamin D, Calcium, and Vitamin D Receptor Polymorphism in Colorectal Adenomas Cancer Epidemiol. Biomarkers Prev., December 1, 2001; 10(12): 1267 - 1274. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-W. Yu, Y.-C. Yang, S.-Y. Yang, S.-W. Cheng, Y.-F. Liaw, S.-M. Lin, and C.-J. Chen Hormonal Markers and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: a Nested Case-Control Study Among Men J Natl Cancer Inst, November 7, 2001; 93(21): 1644 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M Chan, M. J Stampfer, J. Ma, P. H Gann, J M. Gaziano, and E. L Giovannucci Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study Am. J. Clinical Nutrition, October 1, 2001; 74(4): 549 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Moffatt, W. U. Johannes, T. E. Hedlund, and G. J. Miller Growth Inhibitory Effects of 1{alpha}, 25-Dihydroxyvitamin D3 Are Mediated by Increased Levels of p21 in the Prostatic Carcinoma Cell Line ALVA-31 Cancer Res., October 1, 2001; 61(19): 7122 - 7129. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Modugno, J. L. Weissfeld, D. L. Trump, J. M. Zmuda, P. Shea, J. A. Cauley, and R. E. Ferrell Allelic Variants of Aromatase and the Androgen and Estrogen Receptors: Toward a Multigenic Model of Prostate Cancer Risk Clin. Cancer Res., October 1, 2001; 7(10): 3092 - 3096. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Luscombe, M. E. French, S. Liu, M. F. Saxby, P. W. Jones, A. A. Fryer, and R. C. Strange Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes Carcinogenesis, September 1, 2001; 22(9): 1343 - 1347. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Taplin and S.-M. Ho The Endocrinology of Prostate Cancer J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477. [Full Text] [PDF] |
||||
![]() |
Y. Giguere, E. Dewailly, J. Brisson, P. Ayotte, N. Laflamme, A. Demers, V.-I. Forest, S. Dodin, J. Robert, and F. Rousseau Short Polyglutamine Tracts in the Androgen Receptor Are Protective against Breast Cancer in the General Population Cancer Res., August 1, 2001; 61(15): 5869 - 5874. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-M. Xue, G. A. Coetzee, R. K. Ross, R. Irvine, L. Kolonel, B. E. Henderson, and S. A. Ingles Genetic Determinants of Serum Prostate-specific Antigen levels in Healthy Men from a Multiethnic Cohort Cancer Epidemiol. Biomarkers Prev., June 1, 2001; 10(6): 575 - 579. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Buchanan, N. M. Greenberg, H. I. Scher, J. M. Harris, V. R. Marshall, and W. D. Tilley Collocation of Androgen Receptor Gene Mutations in Prostate Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1273 - 1281. [Abstract] [Full Text] |
||||
![]() |
E. A. Platz, E. B. Rimm, W. C. Willett, P. W. Kantoff, and E. Giovannucci Racial Variation in Prostate Cancer Incidence and in Hormonal System Markers Among Male Health Professionals J Natl Cancer Inst, December 20, 2000; 92(24): 2009 - 2017. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-W. Yu, S.-W. Cheng, M.-W. Lin, S.-Y. Yang, Y.-F. Liaw, H.-C. Chang, T.-J. Hsiao, S.-M. Lin, S.-D. Lee, P.-J. Chen, et al. Androgen-Receptor Gene CAG Repeats, Plasma Testosterone Levels, and Risk of Hepatitis B-Related Hepatocellular Carcinoma J Natl Cancer Inst, December 20, 2000; 92(24): 2023 - 2028. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ban, M. Taniyama, and Y. Ban Vitamin D Receptor Gene Polymorphism Is Associated with Graves' Disease in the Japanese Population J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4639 - 4643. [Abstract] [Full Text] |
||||
![]() |
N. Mononen, K. Syrjäkoski, M. Matikainen, T. L. J. Tammela, J. Schleutker, O.-P. Kallioniemi, J. Trapman, and P. A. Koivisto Two Percent of Finnish Prostate Cancer Patients Have a Germ-line Mutation in the Hormone-binding Domain of the Androgen Receptor Gene Cancer Res., November 1, 2000; 60(22): 6479 - 6481. [Abstract] [Full Text] |
||||
![]() |
A. W. Hsing, Y.-T. Gao, G. Wu, X. Wang, J. Deng, Y.-L. Chen, I. A. Sesterhenn, F. K. Mostofi, J. Benichou, and C. Chang Polymorphic CAG and GGN Repeat Lengths in the Androgen Receptor Gene and Prostate Cancer Risk: A Population-based Case-Control Study in China Cancer Res., September 1, 2000; 60(18): 5111 - 5116. [Abstract] [Full Text] |
||||
![]() |
J D Simmons, C Mullighan, K I Welsh, and D P Jewell Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility Gut, August 1, 2000; 47(2): 211 - 214. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Bosland Chapter 2: The Role of Steroid Hormones in Prostate Carcinogenesis J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 39 - 66. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Lange, H. Chen, K. Brierley, H. Livermore, K. J. Wojno, C. D. Langefeld, K. Lange, and K. A. Cooney The Polymorphic Exon 1 Androgen Receptor CAG Repeat in Men with a Potential Inherited Predisposition to Prostate Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2000; 9(4): 439 - 442. [Abstract] [Full Text] |
||||
![]() |
B. E. Henderson and H. S. Feigelson Hormonal carcinogenesis Carcinogenesis, March 1, 2000; 21(3): 427 - 433. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Xue, R. A. Irvine, M. C. Yu, R. K. Ross, G. A. Coetzee, and S. A. Ingles Susceptibility to Prostate Cancer: Interaction between Genotypes at the Androgen Receptor and Prostate-specific Antigen Loci Cancer Res., February 1, 2000; 60(4): 839 - 841. [Abstract] [Full Text] |
||||
![]() |
P. E. Hutchinson, J. E. Osborne, J. T. Lear, A. G. Smith, P. W. Bowers, P. N. Morris, P. W. Jones, C. York, R. C. Strange, and A. A. Fryer Vitamin D Receptor Polymorphisms Are Associated with Altered Prognosis in Patients with Malignant Melanoma Clin. Cancer Res., February 1, 2000; 6(2): 498 - 504. [Abstract] [Full Text] |
||||
![]() |
R. A. Irvine, H. Ma, M. C. Yu, R. K. Ross, M. R. Stallcup, and G. A. Coetzee Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length Hum. Mol. Genet., January 22, 2000; 9(2): 267 - 274. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Habuchi, T. Suzuki, R. Sasaki, L. Wang, K. Sato, S. Satoh, T. Akao, N. Tsuchiya, N. Shimoda, Y. Wada, et al. Association of Vitamin D Receptor Gene Polymorphism with Prostate Cancer and Benign Prostatic Hyperplasia in a Japanese Population Cancer Res., January 1, 2000; 60(2): 305 - 308. [Abstract] [Full Text] |
||||
![]() |
G. P. Jarvik, J. L. Stanford, E. L. Goode, R. McIndoe, S. Kolb, M. Gibbs, L. Hood, and E. A. Ostrander Confirmation of Prostate Cancer Susceptibility Genes Using High-Risk Families J Natl Cancer Inst Monographs, December 1, 1999; 1999(26): 81 - 87. [Abstract] [Full Text] |
||||
![]() |
A. M. Dunning, S. McBride, J. Gregory, F. Durocher, N. A. Foster, C. S. Healey, N. Smith, P. D. P. Pharoah, R. N. Luben, D. F. Easton, et al. No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer Carcinogenesis, November 1, 1999; 20(11): 2131 - 2135. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Lunn, D. A. Bell, J. L. Mohler, and J. A. Taylor Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2) Carcinogenesis, September 1, 1999; 20(9): 1727 - 1731. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Spurdle, G. S. Dite, X. Chen, C. J. Mayne, M. C. Southey, L. E. Batten, H. Chy, L. Trute, M. R. E. McCredie, G. G. Giles, et al. Androgen Receptor Exon 1 CAG Repeat Length and Breast Cancer in Women Before Age Forty Years J Natl Cancer Inst, June 2, 1999; 91(11): 961 - 966. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Smith, C. S. Johnson, C. C. Freeman, J. Muindi, J. W. Wilson, and D. L. Trump A Phase I Trial of Calcitriol (1,25-Dihydroxycholecalciferol) in Patients with Advanced Malignancy Clin. Cancer Res., June 1, 1999; 5(6): 1339 - 1345. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Malloy, J. W. Pike, and D. Feldman The Vitamin D Receptor and the Syndrome of Hereditary 1,25-Dihydroxyvitamin D-Resistant Rickets Endocr. Rev., April 1, 1999; 20(2): 156 - 188. [Abstract] [Full Text] |
||||
![]() |
L. N. Kolonel, A. M. Y. Nomura, and R. V. Cooney Dietary Fat and Prostate Cancer: Current Status J Natl Cancer Inst, March 3, 1999; 91(5): 414 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Lokeshwar, G. G. Schwartz, M. G. Selzer, K. L. Burnstein, S.-H. Zhuang, N. L. Block, and L. Binderup Inhibition of Prostate Cancer Metastasis in Vivo: A Comparison of 1,25-Dihydroxyvitamin D (Calcitriol) and EB1089 Cancer Epidemiol. Biomarkers Prev., March 1, 1999; 8(3): 241 - 248. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken Molecular Genetics and Epidemiology of Prostate Carcinoma Endocr. Rev., February 1, 1999; 20(1): 22 - 45. [Abstract] [Full Text] |
||||
![]() |
R. Sinha and N. Caporaso Diet, Genetic Susceptibility and Human Cancer Etiology J. Nutr., February 1, 1999; 129(2): 556 - 556. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Cerhan, A. S. Parker, S. D. Putnam, B. C-H. Chiu, C. F. Lynch, M. B. Cohen, J. C. Torner, and K. P. Cantor Family History and Prostate Cancer Risk in a Population-Based Cohort of Iowa Men Cancer Epidemiol. Biomarkers Prev., January 1, 1999; 8(1): 53 - 60. [Abstract] [Full Text] |
||||
![]() |
C. Lopez-Otin and E. P. Diamandis Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features Endocr. Rev., August 1, 1998; 19(4): 365 - 396. [Abstract] [Full Text] [PDF] |
||||






















